|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scélo G and Brennan P: The epidemiology of
bladder and kidney cancer. Nat Clin Pract Urol. 4:205–217. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM: The global burden of urinary
bladder cancer. Scand J Urol Nephrol (Suppl). 218:12–20. 2008.
View Article : Google Scholar
|
|
4
|
Felix AS, Soliman AS, Khaled H, Zaghloul
MS, Banerjee M, El-Baradie M, El-Kalawy M, Abd-Elsayed AA, Ismail
K, Hablas A, et al: The changing patterns of bladder cancer in
Egypt over the past 26 years. Cancer Causes Control. 19:421–429.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Z, Shi T, Zhang L, Zhu P, Deng M,
Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters
of the ATP binding cassette (ABC) family in multidrug resistance: A
review of the past decade. Cancer Lett. 370:153–164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kruh GD, Belinsky MG, Gallo JM and Lee K:
Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4
as determined from recent studies on gene-disrupted mice. Cancer
Metastasis Rev. 26:5–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kool M, van der Linden M, De Haas M,
Scheffer GL, De Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N,
Scheper RJ, et al: MRP3, an organic anion transporter able to
transport anti-cancer drugs. Proc Natl Acad Sci USA. 96:6914–6919.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA
and Sugiyama Y: cDNA cloning and inducible expression of human
multidrug resistance associated protein 3 (MRP3). FEBS Lett.
433:149–152. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Belinsky MG, Bain LJ, Balsara BB, Testa JR
and Kruh GD: Characterization of MOAT-C and MOAT-D, new members of
the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer
Inst. 90:1735–1741. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kool M, De Haas M, Scheffer GL, Scheper
RJ, van Eijk MJ, Juijn JA, Baas F and Borst P: Analysis of
expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the
multidrug resistance-associated protein gene (MRP1), in human
cancer cell lines. Cancer Res. 57:3537–3547. 1997.PubMed/NCBI
|
|
13
|
Mo W and Zhang JT: Human ABCG2: Structure,
function, and its role in multidrug resistance. Int J Biochem Mol
Biol. 3:1–27. 2012.PubMed/NCBI
|
|
14
|
Fetsch PA, Abati A, Litman T, Morisaki K,
Honjo Y, Mittal K and Bates SE: Localization of the ABCG2
mitoxantrone resistance-associated protein in normal tissues.
Cancer Lett. 235:84–92. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polli JW, Olson KL, Chism JP,
John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S and
Demby VE: An unexpected synergist role of P-glycoprotein and breast
cancer resistance protein on the central nervous system penetration
of the tyrosine kinase inhibitor lapatinib
(N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
GW572016). Drug Metab Dispos. 37:439–442. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gupta N, Martin PM, Miyauchi S, Ananth S,
Herdman AV, Martindale RG, Podolsky R and Ganapathy V:
Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer.
Biochem Biophys Res Commun. 343:571–577. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van den Heuvel-Eibrink MM, Wiemer EA,
Prins A, Meijerink JP, Vossebeld PJ, van der Holt B, Pieters R and
Sonneveld P: Increased expression of the breast cancer resistance
protein (BCRP) in relapsed or refractory acute myeloid leukemia
(AML). Leukemia. 16:833–839. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kielar D, Kaminski WE, Liebisch G, Piehler
A, Wenzel JJ, Möhle C, Heimerl S, Langmann T, Friedrich SO,
Böttcher A, et al: Adenosine triphosphate binding cassette (ABC)
transporters are expressed and regulated during terminal
keratinocyte differentiation: A potential role for ABCA7 in
epidermal lipid reorganization. J Invest Dermatol. 121:465–474.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ussar S and Voss T: MEK1 and MEK2,
different regulators of the G1/S transition. J Biol Chem.
279:43861–43869. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hellemans J, Mortier G, De Paepe A,
Speleman F and Vandesompele J: qBase relative quantification
framework and software for management and automated analysis of
real-time quantitative PCR data. Genome Biol. 8:R192007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nolan T, Hands RE and Bustin SA:
Quantification of mRNA using real-time RT-PCR. Nat Protoc.
1:1559–1582. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Burns MJ, Nixon GJ, Foy CA and Harris N:
Standardisation of data from real-time quantitative PCR methods -
evaluation of outliers and comparison of calibration curves. BMC
Biotechnol. 5:312005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maliepaard M, Scheffer GL, Faneyte IF, van
Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper
RJ and Schellens JH: Subcellular localization and distribution of
the breast cancer resistance protein transporter in normal human
tissues. Cancer Res. 61:3458–3464. 2001.PubMed/NCBI
|
|
25
|
Doyle LA, Yang W, Abruzzo LV, Krogmann T,
Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter
from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA.
95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miyake K, Mickley L, Litman T, Zhan Z,
Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, et
al: Molecular cloning of cDNAs which are highly overexpressed in
mitoxantrone-resistant cells: Demonstration of homology to ABC
transport genes. Cancer Res. 59:8–13. 1999.PubMed/NCBI
|
|
27
|
Robey RW, Polgar O, Deeken J, To KW and
Bates SE: ABCG2: Determining its relevance in clinical drug
resistance. Cancer Metastasis Rev. 26:39–57. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Robey RW, To KK, Polgar O, Dohse M, Fetsch
P, Dean M and Bates SE: ABCG2: A perspective. Adv Drug Deliv Rev.
61:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mao Q and Unadkat JD: Role of the breast
cancer resistance protein (ABCG2) in drug transport. AAPS J.
7:E118–E133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Natarajan K, Xie Y, Baer MR and Ross DD:
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer
drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bustin SA, Benes V, Nolan T and Pfaffl MW:
Quantitative real-time RT-PCR - a perspective. J Mol Endocrinol.
34:597–601. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kubista M, Andrade JM, Bengtsson M,
Forootan A, Jonák J, Lind K, Sindelka R, Sjöback R, Sjögreen B,
Strömbom L, et al: The real-time polymerase chain reaction. Mol
Aspects Med. 27:95–125. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burger H, Foekens JA, Look MP, Meijer-van
Gelder ME, Klijn JG, Wiemer EA, Stoter G and Nooter K: RNA
expression of breast cancer resistance protein, lung
resistance-related protein, multidrug resistance-associated
proteins 1 and 2, and multidrug resistance gene 1 in breast cancer:
Correlation with chemotherapeutic response. Clin Cancer Res.
9:827–836. 2003.PubMed/NCBI
|
|
34
|
Wong ML and Medrano JF: Real-time PCR for
mRNA quantitation. Biotechniques. 39:75–85. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huggett J, Dheda K, Bustin S and Zumla A:
Real-time RT-PCR normalisation; strategies and considerations.
Genes Immun. 6:279–284. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen B, Dong P, Li D and Gao S: Expression
and function of ABCG2 in head and neck squamous cell carcinoma and
cell lines. Exp Ther Med. 2:1151–1157. 2011.PubMed/NCBI
|
|
37
|
Partanen L, Staaf J, Tanner M, Tuominen
VJ, Borg Å and Isola J: Amplification and overexpression of the
ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes
Cancer. 51:832–840. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Diestra JE, Scheffer GL, Català I,
Maliepaard M, Schellens JH, Scheper RJ, Germà-Lluch JR and
Izquierdo MA: Frequent expression of the multi-drug
resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours
detected by the BXP-21 monoclonal antibody in paraffin-embedded
material. J Pathol. 198:213–219. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Scheffer GL, Maliepaard M, Pijnenborg AC,
van Gastelen MA, De Jong MC, Schroeijers AB, van der Kolk DM, Allen
JD, Ross DD, van der Valk P, et al: Breast cancer resistance
protein is localized at the plasma membrane in mitoxantrone- and
topotecan-resistant cell lines. Cancer Res. 60:2589–2593.
2000.PubMed/NCBI
|
|
40
|
Diestra JE, Condom E, Del Muro XG,
Scheffer GL, Pérez J, Zurita AJ, Muñoz-Seguí J, Vigués F, Scheper
RJ, Capellá G, et al: Expression of multidrug resistance proteins
P-glycoprotein, multidrug resistance protein 1, breast cancer
resistance protein and lung resistance related protein in locally
advanced bladder cancer treated with neoadjuvant chemotherapy:
Biological and clinical implications. J Urol. 170:1383–1387. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Faneyte IF, Kristel PM, Maliepaard M,
Scheffer GL, Scheper RJ, Schellens JH and van de Vijver MJ:
Expression of the breast cancer resistance protein in breast
cancer. Clin Cancer Res. 8:1068–1074. 2002.PubMed/NCBI
|
|
42
|
Kanzaki A, Toi M, Nakayama K, Bando H,
Mutoh M, Uchida T, Fukumoto M and Takebayashi Y: Expression of
multidrug resistance-related transporters in human breast
carcinoma. Jpn J Cancer Res. 92:452–458. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Candeil L, Gourdier I, Peyron D, Vezzio N,
Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, et
al: ABCG2 overexpression in colon cancer cells resistant to SN38
and in irinotecan-treated metastases. Int J Cancer. 109:848–854.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Aust S, Obrist P, Jaeger W, Klimpfinger M,
Tucek G, Wrba F, Penner E and Thalhammer T: Subcellular
localization of the ABCG2 transporter in normal and malignant human
gallbladder epithelium. Lab Invest. 84:1024–1036. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
King HC and Sinha AA: Gene expression
profile analysis by DNA microarrays: Promise and pitfalls. JAMA.
286:2280–2288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
van Herwaarden AE, Wagenaar E, Karnekamp
B, Merino G, Jonker JW and Schinkel AH: Breast cancer resistance
protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary
carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their
secretion into breast milk. Carcinogenesis. 27:123–130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
van Herwaarden AE, Jonker JW, Wagenaar E,
Brinkhuis RF, Schellens JH, Beijnen JH and Schinkel AH: The breast
cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the
dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b)pyridine.
Cancer Res. 63:6447–6452. 2003.PubMed/NCBI
|
|
48
|
Ebert B, Seidel A and Lampen A:
Identification of BCRP as transporter of benzo[a)pyrene conjugates
metabolically formed in Caco-2 cells and its induction by
Ah-receptor agonists. Carcinogenesis. 26:1754–1763. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Enokizono J, Kusuhara H, Ose A, Schinkel
AH and Sugiyama Y: Quantitative investigation of the role of breast
cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis
penetration of xenobiotic compounds. Drug Metab Dispos.
36:995–1002. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jonker JW, Buitelaar M, Wagenaar E, Van
Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink
RP, Rosing H, et al: The breast cancer resistance protein protects
against a major chlorophyll-derived dietary phototoxin and
protoporphyria. Proc Natl Acad Sci USA. 99:15649–15654. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Robey RW, Steadman K, Polgar O and Bates
SE: ABCG2-mediated transport of photosensitizers: Potential impact
on photodynamic therapy. Cancer Biol Ther. 4:187–194. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Krishnamurthy P, Ross DD, Nakanishi T,
Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP and
Schuetz JD: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell
survival through interactions with heme. J Biol Chem.
279:24218–24225. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Susanto J, Lin YH, Chen YN, Shen CR, Yan
YT, Tsai ST, Chen CH and Shen CN: Porphyrin homeostasis maintained
by ABCG2 regulates self-renewal of embryonic stem cells. PLoS One.
3:e40232008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Segawa Y, Oda Y, Yamamoto H, Uryu H,
Shiratsuchi H, Hirakawa N, Tomita K, Yamamoto T, Oda S, Yamada T,
et al: Overexpression of inducible nitric oxide synthase and
accumulation of 8-OHdG in nasopharyngeal carcinoma. Histopathology.
52:213–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xu W, Liu LZ, Loizidou M, Ahmed M and
Charles IG: The role of nitric oxide in cancer. Cell Res.
12:311–320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
König J, Hartel M, Nies AT, Martignoni ME,
Guo J, Büchler MW, Friess H and Keppler D: Expression and
localization of human multidrug resistance protein (ABCC) family
members in pancreatic carcinoma. Int J Cancer. 115:359–367. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tada Y, Wada M, Migita T, Nagayama J,
Hinoshita E, Mochida Y, Maehara Y, Tsuneyoshi M, Kuwano M and Naito
S: Increased expression of multidrug resistance-associated proteins
in bladder cancer during clinical course and drug resistance to
doxorubicin. Int J Cancer. 98:630–635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
O'Brien C, Cavet G, Pandita A, Hu X, Haydu
L, Mohan S, Toy K, Rivers CS, Modrusan Z, Amler LC, et al:
Functional genomics identifies ABCC3 as a mediator of taxane
resistance in HER2-amplified breast cancer. Cancer Res.
68:5380–5389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zeng H, Bain LJ, Belinsky MG and Kruh GD:
Expression of multidrug resistance protein-3 (multispecific organic
anion transporter-D) in human embryonic kidney 293 cells confers
resistance to anticancer agents. Cancer Res. 59:5964–5967.
1999.PubMed/NCBI
|
|
60
|
Young LC, Campling BG, Voskoglou-Nomikos
T, Cole SP, Deeley RG and Gerlach JH: Expression of multidrug
resistance protein-related genes in lung cancer: Correlation with
drug response. Clin Cancer Res. 5:673–680. 1999.PubMed/NCBI
|
|
61
|
Ifergan I, Shafran A, Jansen G, Hooijberg
JH, Scheffer GL and Assaraf YG: Folate deprivation results in the
loss of breast cancer resistance protein (BCRP/ABCG2) expression. A
role for BCRP in cellular folate homeostasis. J Biol Chem.
279:25527–25534. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen ZS, Robey RW, Belinsky MG,
Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE and Kruh GD:
Transport of methotrexate, methotrexate polyglutamates, and
17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: Effects of
acquired mutations at R482 on methotrexate transport. Cancer Res.
63:4048–4054. 2003.PubMed/NCBI
|
|
63
|
Volk EL and Schneider E: Wild-type breast
cancer resistance protein (BCRP/ABCG2) is a methotrexate
polyglutamate transporter. Cancer Res. 63:5538–5543.
2003.PubMed/NCBI
|
|
64
|
Hardwick LJ, Velamakanni S and van Veen
HW: The emerging pharmacotherapeutic significance of the breast
cancer resistance protein (ABCG2). Br J Pharmacol. 151:163–174.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zeng H, Chen ZS, Belinsky MG, Rea PA and
Kruh GD: Transport of methotrexate (MTX) and folates by multidrug
resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on
MTX transport. Cancer Res. 61:7225–7232. 2001.PubMed/NCBI
|
